A retrospective, multicenter study of safety and efficacy of nivolumab in patients with head and neck squamous cell carcinoma
Latest Information Update: 10 Aug 2022
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 01 Sep 2022 Results published in the Oral Oncology
- 13 Jun 2022 New trial record